Peptides for Liver Support and Detox: BPC-157, LL-37, and Hepatoprotection

The liver performs over 500 distinct functions: filtering toxins, synthesizing proteins, metabolizing drugs and hormones, producing bile, regulating blood sugar, and storing vitamins. When it is overwhelmed — by alcohol, medications, metabolic syndrome, or chronic inflammatory conditions — the downstream effects touch virtually every system in the body.

Peptide therapy for liver support is an emerging area with a compelling evidence base, particularly for BPC-157. This guide covers the peptides with the most documented hepatoprotective activity, how they work, and how to use them practically.

Why the Liver Is Difficult to Protect

The liver is uniquely vulnerable because of its role as the first stop for nutrients, toxins, and drugs absorbed from the gut (via the portal vein). It is exposed to high concentrations of potentially damaging substances before the rest of the body. Common threats include:

• Alcohol: Produces acetaldehyde and reactive oxygen species; promotes fatty liver and fibrosis
• NSAIDs and acetaminophen: Hepatotoxic at high doses through oxidative stress and mitochondrial damage
• Non-alcoholic fatty liver disease (NAFLD): Driven by metabolic dysfunction, increasingly prevalent
• Inflammatory conditions: Systemic inflammation drives hepatic inflammation and fibrosis
• Mycotoxins: Mold toxins (especially aflatoxins) directly damage hepatocytes

The liver has remarkable regenerative capacity, but chronic or repeated insult eventually leads to fibrosis and, in severe cases, cirrhosis. Peptides that reduce hepatic inflammation, support hepatocyte survival, and accelerate regeneration address these vulnerabilities directly.

BPC-157: The Most Documented Liver Peptide

BPC-157 (Body Protection Compound-157) was originally isolated from human gastric juice and named for its cytoprotective properties in the gastrointestinal tract. Its hepatoprotective effects are among the most well-documented in the peptide literature.

BPC-157 Mechanisms for Liver Protection

Counteracts alcohol-induced liver damage. Multiple animal studies show BPC-157 prevents and reverses the liver damage caused by acute and chronic alcohol administration. Specifically, it normalizes liver enzyme levels (AST, ALT), reduces hepatic fat accumulation, and protects hepatocytes from acetaldehyde-induced cell death.

NSAID and acetaminophen protection. BPC-157 has been shown to protect the liver from the hepatotoxic effects of NSAIDs (including indomethacin and aspirin at hepatotoxic doses) and to reduce acetaminophen-induced liver injury in animal models. This is particularly relevant for people who regularly use these medications.

Reversal of established fatty liver. In animal models of NAFLD, BPC-157 reduces hepatic triglyceride accumulation and liver-to-body weight ratio — markers of fatty liver severity.

Reduction of liver fibrosis markers. BPC-157 reduces transforming growth factor-beta (TGF-β) — a primary driver of hepatic fibrosis — and inhibits stellate cell activation, the cellular process that converts liver inflammation into fibrotic scar tissue.

Portal hypertension and vascular effects. Through its nitric oxide-modulating properties, BPC-157 improves hepatic blood flow, relevant in conditions where portal hypertension is a concern.

BPC-157 Protocol for Liver Support

• Dose: 250–500 mcg per day
• Route: Oral capsule or liquid is the preferred route for gut-liver axis effects (peptide is absorbed from the gut into the portal circulation, delivering it directly to the liver)
• Timing: On an empty stomach, morning and/or evening
• Cycle: 8–12 weeks for established liver stress; ongoing lower-dose use for maintenance in high-risk individuals

The oral route has an advantage here: BPC-157 absorbed from the gut enters the portal vein and is delivered directly to the liver before reaching systemic circulation. This first-pass delivery may enhance hepatic concentration. See the full BPC-157 guide for complete dosing information.

LL-37: Antimicrobial Defense and Liver Inflammation

LL-37 is the only member of the cathelicidin family of antimicrobial peptides in humans. It is produced by neutrophils, macrophages, and epithelial cells and plays a critical role in innate immune defense against bacterial, viral, and fungal threats.

LL-37 and Liver Health

The liver is a central node of immune function, and LL-37 is relevant to several hepatic conditions:

Bacterial translocation and SIBO. One of the drivers of liver inflammation — particularly in alcohol-related liver disease and NAFLD — is bacterial translocation from the gut. Lipopolysaccharides (LPS) from gram-negative bacteria enter the portal circulation and trigger hepatic inflammation via Toll-like receptors. LL-37 combats gram-negative bacteria, reduces LPS burden, and modulates the TLR4 signaling pathway that drives this LPS-induced liver inflammation.

Antiviral activity. LL-37 has demonstrated activity against hepatitis C virus (HCV) in cell culture models, suggesting a potential supportive role in viral hepatitis contexts.

Modulation of hepatic macrophages (Kupffer cells). LL-37 modulates Kupffer cell activity — the liver's resident macrophages responsible for clearing pathogens and initiating inflammatory responses. Dysregulated Kupffer cell activity drives much of the inflammatory liver damage in NAFLD and alcohol-related liver disease.

LL-37 Protocol Considerations

LL-37 is more specialized than BPC-157 and less commonly used for liver-specific applications. It is typically used at doses of 100–300 mcg subcutaneously, with protocols tailored to the specific underlying condition. Due to its potent immune-modulating effects, it should be approached carefully and ideally under medical guidance.

NAD+ Peptides and Mitochondrial Support

NAD+ (nicotinamide adenine dinucleotide) is not a peptide itself, but NAD+ precursors (NMN, NR) and related compounds support hepatic mitochondrial function that is central to liver detoxification capacity. Hepatocytes have among the highest mitochondrial density of any cell in the body, and mitochondrial dysfunction is a key feature of alcoholic liver disease and NAFLD.

The SS-31 peptide (also called Elamipretide) is directly relevant here. SS-31 targets the inner mitochondrial membrane, where it protects cardiolipin and prevents mitochondrial permeability transition — a process that drives hepatocyte death under oxidative stress conditions. Animal studies show SS-31 reduces liver injury markers and hepatocyte apoptosis in models of acute liver stress. See our SS-31 mitochondria guide for details.

GHK-Cu: Tissue Remodeling and Anti-Fibrotic Action

GHK-Cu (copper peptide) has emerged as a potential anti-fibrotic agent in the liver through its ability to modulate TGF-β and promote tissue remodeling. In the liver, TGF-β signaling drives hepatic stellate cell activation and collagen deposition — the process by which chronic inflammation converts to fibrosis.

GHK-Cu also upregulates antioxidant enzymes (superoxide dismutase, catalase) that protect hepatocytes from oxidative damage. While dedicated liver-focused human research is limited, its anti-fibrotic mechanisms are directly relevant to conditions like NAFLD with early fibrosis. See the GHK-Cu guide.

Practical Protocol for Liver Support

For general liver protection (high alcohol use, regular NSAID use, or metabolic stress):

BPC-157 oral: 250 mcg twice daily on an empty stomach for 8–12 weeks. This is the cornerstone of a liver support protocol.

Supporting measures: Milk thistle (silymarin), N-acetylcysteine (NAC) for glutathione support, and alpha lipoic acid (ALA) all have clinical evidence for hepatoprotection and complement the BPC-157 mechanism.

For NAFLD or established liver inflammation:

BPC-157 oral + SS-31 (subcutaneous): BPC-157 handles the gut-liver axis and fibrosis reduction; SS-31 supports hepatic mitochondrial function. 8–12 weeks of each.

For gut bacterial translocation driving liver inflammation:

BPC-157 (oral, for gut healing) + LL-37 (subcutaneous, for antimicrobial immune support): Address both the gut barrier and the bacterial burden driving hepatic TLR4 activation.

What Peptides Cannot Do

Peptides support the liver's own healing processes — they are hepatoprotective and regenerative. They cannot reverse established cirrhosis (end-stage fibrosis where functional liver tissue has been replaced by scar). They are not a substitute for eliminating the ongoing source of liver damage. The most important intervention for alcohol-related liver disease is reducing alcohol consumption; for NAFLD, it is weight loss, metabolic improvement, and dietary change.

Peptides are most powerful as adjuncts when the primary stressor is being addressed simultaneously.

Monitoring Liver Health

If using peptides for liver support — especially alongside ongoing hepatic stressors — monitoring with liver function tests provides objective feedback:

• ALT (alanine aminotransferase): Most specific marker of hepatocyte damage
• AST (aspartate aminotransferase): Liver damage; also elevated in muscle injury
• GGT (gamma-glutamyl transferase): Sensitive marker of alcohol exposure and oxidative liver stress
• Alkaline phosphatase: Biliary and liver function
• Albumin and total protein: Markers of synthetic liver function
• Bilirubin: Liver processing and bile excretion

Testing before and after a 12-week peptide protocol provides clear evidence of whether liver enzymes have normalized.

Frequently Asked Questions

Q: Can BPC-157 repair liver damage from alcohol? Animal research shows BPC-157 normalizes liver enzymes elevated by alcohol exposure, reduces hepatic fat accumulation, and protects hepatocytes from acetaldehyde damage. Human clinical trials have not been conducted, but the animal evidence is compelling. It is not a license to continue heavy drinking — it is a hepatoprotective tool for people managing or recovering from alcohol-related liver stress.

Q: Is oral BPC-157 better than injectable for liver health? For liver applications specifically, oral administration may have an advantage because BPC-157 absorbed from the gut enters the portal vein and is delivered directly to the liver in higher concentrations before reaching systemic circulation. This first-pass delivery is relevant for hepatic conditions.

Q: Can peptides help with fatty liver (NAFLD)? BPC-157 has shown reduced hepatic triglyceride accumulation and fibrosis markers in NAFLD animal models. GHK-Cu and SS-31 address related aspects of the condition (fibrosis and mitochondrial dysfunction). None have been studied in human NAFLD trials yet.

Q: Is it safe to use BPC-157 while drinking alcohol regularly? BPC-157 is not a replacement for moderating alcohol intake. Its hepatoprotective effects are beneficial alongside moderate alcohol use or during a reduction/cessation period, but they cannot fully counteract the damage of heavy, chronic drinking. The liver needs the primary insult reduced.

Q: What supplements work well alongside BPC-157 for liver support? NAC (N-acetylcysteine) for glutathione precursor support, silymarin (milk thistle) for hepatocyte membrane stabilization, and alpha lipoic acid for antioxidant protection all have clinical evidence and complement BPC-157's mechanisms without known adverse interactions.

Q: How long before I see liver enzyme improvements? If alcohol or NSAID use is the primary driver and is being moderated, liver enzymes can normalize within 4–8 weeks with BPC-157 support. NAFLD-related changes take longer — 12+ weeks is a more realistic timeline.